TW202229316A - 肽、ｓａｒｓ脂質－肽融合體、ｓａｒｓ脂質－肽融合抑制劑、藥物組成物、ｓａｒｓ－ｃｏｖ－２（ｃｏｖｉｄ－１９）抗病毒組成物及用途 - Google Patents

肽、ｓａｒｓ脂質－肽融合體、ｓａｒｓ脂質－肽融合抑制劑、藥物組成物、ｓａｒｓ－ｃｏｖ－２（ｃｏｖｉｄ－１９）抗病毒組成物及用途 Download PDF

Info

Publication number
TW202229316A
TW202229316A TW110138190A TW110138190A TW202229316A TW 202229316 A TW202229316 A TW 202229316A TW 110138190 A TW110138190 A TW 110138190A TW 110138190 A TW110138190 A TW 110138190A TW 202229316 A TW202229316 A TW 202229316A
Authority
TW
Taiwan
Prior art keywords
sars
cov
peptide
covid
subject
Prior art date
Application number
TW110138190A
Other languages
English (en)
Chinese (zh)
Inventor
馬特奧 波羅托
安妮 莫斯科納
蒂齊安娜 弗朗西斯卡 博維爾
斯瓦特 瑞克 德
弗里斯 羅里 德
布蘭卡 霍瓦特
西里爾 馬修
Original Assignee
紐約市哥倫比亞大學理事會
伊拉斯謨大學醫學中心
法國國家醫療衛生研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 紐約市哥倫比亞大學理事會, 伊拉斯謨大學醫學中心, 法國國家醫療衛生研究院 filed Critical 紐約市哥倫比亞大學理事會
Publication of TW202229316A publication Critical patent/TW202229316A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
TW110138190A 2020-10-14 2021-10-14 肽、ｓａｒｓ脂質－肽融合體、ｓａｒｓ脂質－肽融合抑制劑、藥物組成物、ｓａｒｓ－ｃｏｖ－２（ｃｏｖｉｄ－１９）抗病毒組成物及用途 TW202229316A (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US202063091915P 2020-10-14 2020-10-14
US63/091,915 2020-10-14
US202063107429P 2020-10-29 2020-10-29
US63/107,429 2020-10-29
US202163139302P 2021-01-19 2021-01-19
US202163139306P 2021-01-19 2021-01-19
US63/139,302 2021-01-19
US63/139,306 2021-01-19
US202163144606P 2021-02-02 2021-02-02
US63/144,606 2021-02-02
US202163145453P 2021-02-03 2021-02-03
US63/145,453 2021-02-03

Publications (1)

Publication Number Publication Date
TW202229316A true TW202229316A (zh) 2022-08-01

Family

ID=81208578

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110138190A TW202229316A (zh) 2020-10-14 2021-10-14 肽、ｓａｒｓ脂質－肽融合體、ｓａｒｓ脂質－肽融合抑制劑、藥物組成物、ｓａｒｓ－ｃｏｖ－２（ｃｏｖｉｄ－１９）抗病毒組成物及用途

Country Status (8)

Country Link
US (1) US20240226304A1 (https=)
EP (1) EP4228673A4 (https=)
JP (1) JP2024504225A (https=)
KR (1) KR20240038643A (https=)
CA (1) CA3195563A1 (https=)
IL (1) IL302066A (https=)
TW (1) TW202229316A (https=)
WO (1) WO2022081711A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159372A1 (en) * 2021-01-22 2022-07-28 Decoy Therapeutics, Inc. Methods and compositions for treating infections
CA3235784A1 (en) * 2021-10-22 2023-04-27 Wisconsin Alumni Research Foundation Peptides that inhibit infection by sars-cov-2, the virus that causes covid-19 disease
WO2024016011A2 (en) * 2022-07-15 2024-01-18 The Trustees Of Columbia University In The City Of New York Broad spectrum inhibition of human coronaviruses by lipopeptides derived from the c-terminal heptad repeat of betacoronaviruses
CN115746148B (zh) * 2022-10-14 2023-09-12 中国医学科学院病原生物学研究所 具有冠状病毒rbd和膜融合抑制多肽的蛋白质及其作为冠状病毒抑制剂的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5788178B2 (ja) * 2008-01-23 2015-09-30 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ウィルス感染症の治療のための組成物及び方法
US10172961B2 (en) * 2014-05-07 2019-01-08 Cornell University Inhibitors of fusion between viral and cell membranes as well as compositions and methods of using them
CA3094136A1 (en) * 2018-01-31 2019-08-08 Verra Therapeutics LLC Methods and compositions for inhibiting adam9 biological activities
CN111732637B (zh) * 2020-05-25 2022-03-01 上海交通大学 抑制新型冠状病毒SARS-CoV-2感染宿主细胞的多肽及其应用
CN111560054A (zh) * 2020-06-16 2020-08-21 哈尔滨吉象隆生物技术有限公司 抑制新型冠状病毒感染的多肽及其筛选方法

Also Published As

Publication number Publication date
IL302066A (en) 2023-06-01
WO2022081711A1 (en) 2022-04-21
CA3195563A1 (en) 2022-04-21
US20240226304A1 (en) 2024-07-11
JP2024504225A (ja) 2024-01-31
EP4228673A4 (en) 2024-11-20
WO2022081711A4 (en) 2022-06-30
EP4228673A1 (en) 2023-08-23
KR20240038643A (ko) 2024-03-25

Similar Documents

Publication Publication Date Title
TW202229316A (zh) 肽、ｓａｒｓ脂質－肽融合體、ｓａｒｓ脂質－肽融合抑制劑、藥物組成物、ｓａｒｓ－ｃｏｖ－２（ｃｏｖｉｄ－１９）抗病毒組成物及用途
AU2012343981B2 (en) Influenza virus vaccines and uses thereof
EP3166963B1 (en) Influenza virus vaccines and uses thereof
Zhou et al. Development of variant‐proof severe acute respiratory syndrome coronavirus 2, pan‐sarbecovirus, and pan‐β‐coronavirus vaccines
M. Costello et al. Targeting RSV with vaccines and small molecule drugs
US20260000750A1 (en) Rsv virus-like particles and methods of use thereof
US20240252617A1 (en) Coronavirus spike protein designs, compositions and methods for their use
US12440552B2 (en) Methods for immunizing pre-immune subjects against respiratory syncytial virus (RSV)
Yeung et al. Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention
US20230270843A1 (en) Post-Exposure Vaccination Against Viral Respiratory Infections
US20230159597A1 (en) Lipid-peptide fusion inhibitors as sars-cov-2 antivirals
San-Juan-Vergara et al. Importance of Virus Characteristics in Respiratory Syncytial Virus Induced Disease
Zandi et al. The Spike Protein Mutations and its Effect on SARS-CoV-2 Pathogenesis
CN117915936A (zh) 作为sars-cov-2抗病毒物的脂质肽融合抑制剂
US20250257099A1 (en) Broad spectrum inhibition of human coronaviruses by lipopeptides derived from the c-terminal heptad repeat of betacoronaviruses
Lainšcek et al. A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response. Vaccines 2021, 9, 431
Munro et al. Development of a Recombinant Single-Cycle Influenza Viral Vector as an Intranasal Vaccine against SARS-CoV-2 and SARS-like Betacoronaviruses
Wu et al. Sterilizing immunity against SARS-CoV-2 in hamsters conferred by a novel recombinant subunit vaccine
Zhu Respiratory Syncytial Virus Fusion Protein Interaction with its Cellular Receptor, Nucleolin
Zandi et al. The Spike Protein Mutations and its Effect on SARS-CoV-2 Pathogenesis
Shirinova et al. BIOLOGICAL SCIENCES
Zhang et al. Sterilizing immunity against SARS-CoV-2 in hamsters conferred by a novel recombinant subunit vaccine
NZ625973B2 (en) Influenza virus vaccines and uses thereof